Impact of Sex on Ventricular-Vascular Stiffness and Long-Term Outcomes in Heart Failure With Preserved Ejection Fraction: TOPCAT Trial Substudy

Anna L Beale, Shane Nanayakkara, David M Kaye, Anna L Beale, Shane Nanayakkara, David M Kaye

Abstract

Background Women have higher vascular stiffness with aging. The aim of this study was to characterize sex differences in vascular and ventricular structure and function, and to investigate the impact on the primary outcome in the TOPCAT trial (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial). Methods and Results Data from the Americas cohort of the TOPCAT trial were analyzed. Patients with echocardiography (n=654) were compared according to sex, and achievement of the primary end point (a composite of death from cardiovascular causes and heart failure hospitalization) assessed. Echocardiography revealed higher arterial, systolic, and diastolic ventricular elastance and worse ventricular-vascular coupling in women. Women had better overall survival and heart failure hospitalization outcomes (hazard ratio 0.74, 95% CI 0.57-0.98, P=0.034), however, determinants of achievement of the primary outcome differed between the sexes. Pulse pressure was a key determinant of outcome in women (hazard ratio 1.04, 95% CI 1-1.09, P=0.034) whereas in men heart rate (hazard ratio 1.61, 95% CI 1.02-2.52 per 10 mm Hg increase, P=0.04) and B-type natriuretic peptide (hazard ratio 1.01, 95% CI 1-1.02 per 10 ng/mL increase P=0.02) were associated with poorer outcome. Conclusions Outcomes in patients with heart failure with preserved ejection fraction appear to be differentially influenced by key physiological factors that vary according to sex. In women, ventricular-vascular stiffening was the most significant determinant of outcome, whereas in men overall survival was influenced by heart rate and B-type natriuretic peptide; this highlights key sex differences in the pathophysiology and outcomes of heart failure with preserved ejection fraction and warrants further exploration. Clinical Trial Registration URL: https://ichgcp.net/clinical-trials-registry/NCT00094302" title="See in ClinicalTrials.gov">NCT00094302.

Keywords: health outcomes; heart failure; pulse pressure; sex differences.

Figures

Figure 1
Figure 1
Time to primary end point in women and men.
Figure 2
Figure 2
Time to primary end point in women (A) and men (B) according to pulse pressure category. PP indicates pulse pressure.

References

    1. Pandey A, Omar W, Ayers C, LaMonte M, Klein L, Allen NB, Kuller LH, Greenland P, Eaton CB, Gottdiener JS, Lloyd‐Jones DM, Berry JD. Sex and race differences in lifetime risk of heart failure with preserved ejection fraction and heart failure with reduced ejection fraction. Circulation. 2018;137:1814–1823.
    1. Ho JE, Gona P, Pencina MJ, Tu JV, Austin PC, Vasan RS, Kannel WB, D'Agostino RB, Lee DS, Levy D. Discriminating clinical features of heart failure with preserved vs. reduced ejection fraction in the community. Eur Heart J. 2012;33:1734–1741.
    1. Kuch B, Muscholl M, Luchner A, Doring A, Riegger GA, Schunkert H, Hense HW. Gender specific differences in left ventricular adaptation to obesity and hypertension. J Hum Hypertens. 1998;12:685–691.
    1. Biondi‐Zoccai GGL, Abate A, Bussani R, Camilot D, Giorgio FD, Marino MD, Silvestri F, Baldi F, Biasucci LM, Baldi A. Reduced post‐infarction myocardial apoptosis in women: a clue to their different clinical course? Heart. 2005;91:99–101.
    1. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol. 1974;34:29–34.
    1. Kim HL, Kim MA, Oh S, Kim M, Park SM, Yoon HJ, Shin MS, Hong KS, Shin GJ, Shim WJ. Sex difference in the association between metabolic syndrome and left ventricular diastolic dysfunction. Metab Syndr Relat Disord. 2016;14:507–512.
    1. Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, de Ferranti SD, Floyd J, Fornage M, Gillespie C, Isasi CR, Jimenez MC, Jordan LC, Judd SE, Lackland D, Lichtman JH, Lisabeth L, Liu S, Longenecker CT, Mackey RH, Matsushita K, Mozaffarian D, Mussolino ME, Nasir K, Neumar RW, Palaniappan L, Pandey DK, Thiagarajan RR, Reeves MJ, Ritchey M, Rodriguez CJ, Roth GA, Rosamond WD, Sasson C, Towfighi A, Tsao CW, Turner MB, Virani SS, Voeks JH, Willey JZ, Wilkins JT, Wu JH, Alger HM, Wong SS, Muntner P. Heart disease and stroke statistics—2017 update: a report from the American Heart Association. Circulation. 2017;135:e146–e603.
    1. Redfield MM, Jacobsen SJ, Borlaug BA, Rodeheffer RJ, Kass DA. Age‐ and gender‐related ventricular‐vascular stiffening: a community‐based study. Circulation. 2005;112:2254–2262.
    1. Russo C, Jin Z, Palmieri V, Homma S, Rundek T, Elkind MSV, Sacco RL, Di Tullio MR. Arterial stiffness and wave reflection: sex differences and relationship with left ventricular diastolic function. Hypertension. 2012;60:362–368.
    1. Smulyan H, Asmar RG, Rudnicki A, London GM, Safar ME. Comparative effects of aging in men and women on the properties of the arterial tree. J Am Coll Cardiol. 2001;37:1374–1380.
    1. Chester R, Sander G, Fernandez C, Chen W, Berenson G, Giles T. Women have significantly greater difference between central and peripheral arterial pressure compared with men: the Bogalusa Heart Study. J Am Soc Hypertens. 2013;7:379–385.
    1. Reddy YNV, Andersen MJ, Obokata M, Koepp KE, Kane GC, Melenovsky V, Olson TP, Borlaug BA. Arterial stiffening with exercise in patients with heart failure and preserved ejection fraction. J Am Coll Cardiol. 2017;70:136–148.
    1. Crea F, Bairey Merz CN, Beltrame JF, Kaski JC, Ogawa H, Ong P, Sechtem U, Shimokawa H, Camici PG. The parallel tales of microvascular angina and heart failure with preserved ejection fraction: a paradigm shift. Eur Heart J. 2017;38:473–477.
    1. Gori M, Lam CS, Gupta DK, Santos AB, Cheng S, Shah AM, Claggett B, Zile MR, Kraigher‐Krainer E, Pieske B, Voors AA, Packer M, Bransford T, Lefkowitz M, McMurray JJ, Solomon SD. Sex‐specific cardiovascular structure and function in heart failure with preserved ejection fraction. Eur J Heart Fail. 2014;16:535–542.
    1. Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Harty B, Heitner JF, Kenwood CT, Lewis EF, O'Meara E, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, Yang S, McKinlay SM. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370:1383–1392.
    1. Pfeffer MA, Claggett B, Assmann SF, Boineau R, Anand IS, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Heitner JF, Lewis EF, O'Meara E, Rouleau J‐L, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, McKinlay SM, Pitt B. Regional variation in patients and outcomes in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial. Circulation. 2015;131:34–42.
    1. Shah AM, Claggett B, Sweitzer NK, Shah SJ, Anand IS, O'Meara E, Desai AS, Heitner JF, Li G, Fang J, Rouleau J‐L, Zile MR, Markov V, Ryabov V, Reis G, Assmann SF, McKinlay SM, Pitt B, Pfeffer MA, Solomon SD. Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the echocardiographic study of the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial. Circ Heart Fail. 2014;7:740–751.
    1. Reichek N, Wilson J, St John Sutton M, Plappert TA, Goldberg S, Hirshfeld JW. Noninvasive determination of left ventricular end‐systolic stress: validation of the method and initial application. Circulation. 1982;65:99–108.
    1. Niizuma S, Iwanaga Y, Yahata T, Tamaki Y, Goto Y, Nakahama H, Miyazaki S. Impact of left ventricular end‐diastolic wall stress on plasma B‐type natriuretic peptide in heart failure with chronic kidney disease and end‐stage renal disease. Clin Chem. 2009;55:1347–1353.
    1. Ommen SR, Nishimura RA, Appleton CP, Miller FA, Oh JK, Redfield MM, Tajik AJ. Clinical utility of Doppler echocardiography and tissue Doppler imaging in the estimation of left ventricular filling pressures: a comparative simultaneous Doppler‐catheterization study. Circulation. 2000;102:1788–1794.
    1. Borlaug BA, Kass DA. Ventricular‐vascular interaction in heart failure. Heart Fail Clin. 2008;4:23–36.
    1. Kass DA. Assessment of diastolic dysfunction. Invasive modalities. Cardiol Clin. 2000;18:571–586.
    1. Chantler PD, Lakatta EG, Najjar SS. Arterial‐ventricular coupling: mechanistic insights into cardiovascular performance at rest and during exercise. J Appl Physiol (1985). 2008;105:1342–1351.
    1. Lam CS, Carson PE, Anand IS, Rector TS, Kuskowski M, Komajda M, McKelvie RS, McMurray JJ, Zile MR, Massie BM, Kitzman DW. Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the irbesartan in heart failure with preserved ejection fraction (I‐PRESERVE) trial. Circ Heart Fail. 2012;5:571–578.
    1. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise J, Solomon S, Spencer KT, St John Sutton M, Stewart W. American Society of Echocardiography's Nomenclature and Standards Committee; Task Force on Chamber Quantification; American College of Cardiology Echocardiography Committee; American Heart Association; European Association of Echocardiography, European Society of Cardiology . Recommendations for chamber quantification. Eur J Echocardiogr. 2006;7:79–108.
    1. Lam CS, Roger VL, Rodeheffer RJ, Bursi F, Borlaug BA, Ommen SR, Kass DA, Redfield MM. Cardiac structure and ventricular‐vascular function in persons with heart failure and preserved ejection fraction from Olmsted county, Minnesota. Circulation. 2007;115:1982–1990.
    1. Kawaguchi M, Hay I, Fetics B, Kass DA. Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction: implications for systolic and diastolic reserve limitations. Circulation. 2003;107:714–720.
    1. Desai AS, Mitchell GF, Fang JC, Creager MA. Central aortic stiffness is increased in patients with heart failure and preserved ejection fraction. J Card Fail. 2009;15:658–664.
    1. Tsujimoto T, Kajio H. Low diastolic blood pressure and adverse outcomes in heart failure with preserved ejection fraction. Int J Cardiol. 2018;263:69–74.
    1. Warren J, Nanayakkara S, Andrianopoulos N, Brennan A, Selkrig L, Dart A, Clark D, Hiew C, Freeman M, Kingwell B, Duffy S. TCT‐661 impact of pre‐procedural blood pressure on long‐term outcomes following percutaneous coronary intervention. J Am Coll Cardiol. 2017;70:B289–B290.
    1. McEvoy JW, Chen Y, Rawlings A, Hoogeveen RC, Ballantyne CM, Blumenthal RS, Coresh J, Selvin E. Diastolic blood pressure, subclinical myocardial damage, and cardiac events: implications for blood pressure control. J Am Coll Cardiol. 2016;68:1713–1722.
    1. Duca F, Zotter‐Tufaro C, Kammerlander AA, Aschauer S, Binder C, Mascherbauer J, Bonderman D. Gender‐related differences in heart failure with preserved ejection fraction. Sci Rep. 2018;8:1080.
    1. Vedin O, Lam CSP, Koh AS, Benson L, Teng THK, Tay WT, Braun OO, Savarese G, Dahlstrom U, Lund LH. Significance of ischemic heart disease in patients with heart failure and preserved, midrange, and reduced ejection fraction: a nationwide cohort study. Circ Heart Fail. 2017;10:e003875.
    1. Lam CSP, Gamble GD, Ling LH, Sim D, Leong KTG, Yeo PSD, Ong HY, Jaufeerally F, Ng TP, Cameron VA, Poppe K, Lund M, Devlin G, Troughton R, Richards AM, Doughty RN. Mortality associated with heart failure with preserved vs. reduced ejection fraction in a prospective international multi‐ethnic cohort study. Eur Heart J. 2018;39:1770–1780.
    1. Maeder MT, Mariani JA, Kaye DM. Hemodynamic determinants of myocardial B‐type natriuretic peptide release. Hypertension. 2010;56:682–689.
    1. Lam PH, Dooley DJ, Deedwania P, Singh SN, Bhatt DL, Morgan CJ, Butler J, Mohammed SF, Wu WC, Panjrath G, Zile MR, White M, Arundel C, Love TE, Blackman MR, Allman RM, Aronow WS, Anker SD, Fonarow GC, Ahmed A. Heart rate and outcomes in hospitalized patients with heart failure with preserved ejection fraction. J Am Coll Cardiol. 2017;70:1861–1871.
    1. Lam CSP, Voors AA, de Boer RA, Solomon SD, van Veldhuisen DJ. Heart failure with preserved ejection fraction: from mechanisms to therapies. Eur Heart J. 2018;39:2780–2792.
    1. Ponikowski P, Voors A, Anker SD, Bueno H, Cleland JG, Coats A, Falk V, Gonzalez‐Juanatey JR, Harjola V‐P. 2016 ESC guidelines for the diganosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Eur Heart J. 2016;37:2129–2200.
    1. Chung AK, Das SR, Leonard D, Peshock RM, Kazi F, Abdullah SM, Canham RM, Levine BD, Drazner MH. Women have higher left ventricular ejection fractions than men independent of differences in left ventricular volume: the Dallas Heart Study. Circulation. 2006;113:1597–1604.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi